This article examines the global accessibility challenges of Lenacapavir, a groundbreaking HIV prevention drug that demonstrated extraordinary efficacy in clinical trials. It contrasts two perspectives: Gilead Sciences claims rapid progress in making the drug available through voluntary licensing agreements with six generic manufacturers for 120 countries, while critics led by Dr. Andrew Hill argue these agreements exclude crucial middle-income countries representing 23% of global HIV infections. The controversy centers on pricing and accessibility, with Hill calculating generic production could cost $40-95 annually per patient versus Gilead's $40,000 treatment price in high-income markets. Critics suggest compulsory licensing may be necessary if Gilead doesn't modify its approach, citing Colombia's 2024 precedent with dolutegravir. The article notes political shifts threaten HIV funding programs, potentially impacting global distribution efforts. Read More

The topic of this report is a long-acting HIV "vaccine" called Lenacapavir, developed by Gilead Sciences in the United States. Read More

A recent Phase 3 clinical trial (NCT04994509), dubbed "PURPOSE 1," has yielded promising results for a new HIV prevention drug, potentially revolutionizing the field of HIV prophylaxis. The study, conducted by Gilead Sciences, evaluated the safety and efficacy of Lenacapavir, a novel long-acting HIV Read More

In August 2022, Gilead announced that the European Commission (EC) has granted marketing authorization for Sunlenca (Lenacapavir), an innovative treatment for adults with multi-drug resistant HIV infection. The treatment works in combination with other antiretroviral(s) when it isn't Read More

Lenacapavir (Sunlenca, GS-6207) is a groundbreaking HIV drug developed by Gilead Sciences as a component of long-acting antiretroviral therapy. This first-in-class capsid inhibitor was approved by the EC in August 2022 and by the FDA in December 2022. Displaying impressive results in clinical trials Read More

Antiretroviral drugs have evolved significantly over time, with new drugs continuously being developed. The analysis below provides some insights into the development timeline, the focus on drug classes, and the use of drugs in combination formulations.Evolution of Drug ClassesThe following timeline Read More

HIV, or human immunodeficiency virus, is a retrovirus that infects and destroys the immune system's CD4+ T cells, leading to acquired immunodeficiency syndrome (AIDS). But how does this tiny virus manage to invade cells and cause so much damage? Here's an overview. Read More